Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Axsome Therapeutics (AXSM) Shares Outstanding (Diluted Average): 2022-2025

Historic Shares Outstanding (Diluted Average) for Axsome Therapeutics (AXSM) over the last 4 years, with Sep 2025 value amounting to $50.0 million.

  • Axsome Therapeutics' Shares Outstanding (Diluted Average) rose 3.91% to $50.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $50.0 million, marking a year-over-year increase of 3.91%. This contributed to the annual value of $47.9 million for FY2024, which is 5.48% up from last year.
  • According to the latest figures from Q3 2025, Axsome Therapeutics' Shares Outstanding (Diluted Average) is $50.0 million, which was up 1.17% from $49.4 million recorded in Q2 2025.
  • In the past 5 years, Axsome Therapeutics' Shares Outstanding (Diluted Average) ranged from a high of $50.0 million in Q3 2025 and a low of $38.3 million during Q1 2022.
  • Its 3-year average for Shares Outstanding (Diluted Average) is $47.2 million, with a median of $47.6 million in 2024.
  • Data for Axsome Therapeutics' Shares Outstanding (Diluted Average) shows a peak YoY grew of 13.57% (in 2023) over the last 5 years.
  • Axsome Therapeutics' Shares Outstanding (Diluted Average) (Quarterly) stood at $40.7 million in 2022, then climbed by 11.73% to $45.4 million in 2023, then grew by 5.48% to $47.9 million in 2024, then climbed by 3.91% to $50.0 million in 2025.
  • Its Shares Outstanding (Diluted Average) stands at $50.0 million for Q3 2025, versus $49.4 million for Q2 2025 and $48.9 million for Q1 2025.